Insider Trading April 16, 2026 04:59 PM

Plexus President Executes $336,130 Stock Sale Under 10b5-1 Plan

Todd P. Kelsey disposed of 1,500 shares as Plexus shares trade close to their 52-week peak following robust quarterly results

By Jordan Park PLXS
Plexus President Executes $336,130 Stock Sale Under 10b5-1 Plan
PLXS

Plexus CORP President and CEO Todd P. Kelsey sold 1,500 shares of company stock on April 15, 2026, through an established Rule 10b5-1 trading plan. The transaction totaled $336,130 and was reported to the SEC on April 16, 2026. The move coincides with Plexus shares trading near a 52-week high after an 81% gain over the prior year and follows the company's solid first-quarter fiscal 2026 results.

Key Points

  • Todd P. Kelsey, Plexus President and CEO, sold 1,500 shares on April 15, 2026, under a Rule 10b5-1 plan, netting $336,130.
  • The sale was executed at an average price of $224.0867 per share and was reported on a Form 4 filed April 16, 2026; Kelsey now holds 80,291 shares.
  • Plexus reported Q1 fiscal 2026 EPS of $1.78 versus a $1.75 forecast and revenue of $1.07 billion in line with projections; InvestingPro commentary lists the company as appearing overvalued at a $5.96 billion valuation.

Summary: Todd P. Kelsey, President and CEO of Plexus CORP (NASDAQ:PLXS), recorded a sale of 1,500 shares of Plexus common stock on April 15, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The disposition, executed under a pre-established Rule 10b5-1 trading plan adopted November 20, 2025, generated proceeds of $336,130.

The shares were sold at prices spanning from $223.98 to $224.30, producing an average sale price of $224.0867 per share. Following the transaction, Kelsey’s direct holdings in Plexus stand at 80,291 shares. The Form 4 filing was submitted to the SEC on April 16, 2026, and was signed by Kate A. Gitter, Attorney-in-Fact, on Kelsey’s behalf.

Plexus’s stock was trading close to its 52-week high of $232.17 at the time of the sale, after delivering an 81% return over the previous 12 months. Market observers may note the timing of the sale relative to the share price, though the filing shows the trade was made under the previously adopted 10b5-1 plan.

On the fundamentals front, Plexus reported strong results for the first quarter of fiscal 2026. The company posted earnings per share of $1.78, exceeding the forecast of $1.75, while quarterly revenue of $1.07 billion matched expectations. The company’s reported results highlighted its ability to meet and in part surpass analyst projections for the quarter. The filing and company disclosures indicate that no material mergers or acquisitions were announced for Plexus in the period covered by the report, and there have been no recent analyst upgrades or downgrades reported.

Separately, an InvestingPro analysis cited alongside the filing places Plexus at a $5.96 billion valuation and characterizes the company as appearing overvalued. That analysis is said to include 14 additional ProTips for PLXS and highlights a Piotroski Score of 9 for the company.

Is PLXS a bargain right now? The original notice referenced a Fair Value calculator as a fast way to assess valuation, noting the use of a mix of 17 industry valuation models. The article does not add further commentary beyond these references to available tools and the InvestingPro view.


Transaction details (from Form 4):

  • Insider: Todd P. Kelsey, President and CEO
  • Security: Plexus CORP common stock (NASDAQ:PLXS)
  • Shares sold: 1,500
  • Sale date: April 15, 2026
  • Price range: $223.98 to $224.30
  • Average price: $224.0867
  • Proceeds: $336,130
  • Post-transaction holdings: 80,291 shares
  • Trading arrangement: Rule 10b5-1 plan adopted November 20, 2025
  • SEC filing date: April 16, 2026 (signed by Kate A. Gitter, Attorney-in-Fact)

The information above is drawn from the company’s required SEC filing and the firm-level performance and valuation commentary provided alongside that filing. The article focuses on factual disclosure of the insider transaction and the contemporaneous quarterly financial results and valuation commentary; it does not introduce additional interpretive claims or forecasts.

Risks

  • Valuation risk: InvestingPro analysis cited in the filing characterizes Plexus as appearing overvalued at a $5.96 billion valuation, which may affect investor expectations.
  • Price-level uncertainty: Plexus shares were trading near the 52-week high after an 81% one-year gain, a context that can coincide with heightened share-price volatility.
  • Limited external catalysts noted: The filing indicates no significant mergers or acquisitions and no recent analyst upgrades or downgrades, which may leave fewer external drivers for near-term sentiment.

More from Insider Trading

Astera Labs CEO Disposes $518K in Stock Under 10b5-1 Plan Apr 16, 2026 Forager Fund Reduces Stake in Regional Management, Selling $1.44M in Shares Apr 16, 2026 Aura Biosciences Legal Chief Sells Shares to Cover Taxes as Stock Trades Near Year High Apr 16, 2026 Pinterest Director Disposes $42,000 in Stock as Analysts Weigh In Apr 16, 2026 Gilead Executive Sells $422,880 in Stock as Company Advances HIV Access and AI Collaboration Apr 16, 2026